Yang Langyu, Wei Minyan, Deng Xiaohua, He Linlong, Lin Yinshan, Lin Xufeng, Zhou Dazhi, Li Ming, Qin Aiping, Zhang Lingmin, Ouyang Zizhang
The Affiliated Qingyuan Hospital (Qingyuan People's Hospital), Guangzhou Medical University, Qingyuan, Guangdong, 511518, People's Republic of China.
The Affiliated Panyu Central Hospital, The Fifth Affiliated Hospital, Guangzhou Municipal and Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, AIE Pharmaceutical Biology Innovation Research Center, School of Pharmaceutical Sciences, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China.
Int J Nanomedicine. 2025 Aug 24;20:10177-10194. doi: 10.2147/IJN.S536484. eCollection 2025.
Lung cancer has become one of the most fatal cancers at present. Traditional treatments showed limited therapeutic effects on lung cancer. The phototherapy has emerged as a powerful approach for lung cancer treatment. Aggregation-induced emission luminogens (AIEgens) exhibit excellent optical performance such as strong fluorescence, enhanced reactive oxygen species (ROS) generation, and effective thermal effect after aggregation, which show great potential in phototherapy. However, the disadvantages including hydrophobicity, low specificity, and short circulation lifetime limited their efficacy on cancer therapy.
We developed a biomimetic AIEgens constructed using CD8 T cells membrane to camouflage the AIEgen CHNOS (named BITT) nanoparticles (termed TB). The prepared TB improved the tumor accumulation of AIEgen by PD-1/PD-L1 recognition on the CD8 T and LLC cell membranes, respectively.
The prepared TB showed improved binding efficiency, photothermal effects, and ROS generation ability to kill the lung cancer cells. TB also showed improved circulation lifetime and excellent tumor targeting ability, leading to effective phototherapy and immunotherapy in vivo based on BITT and the CD8 T cell-derived membranes. Based on the AIE and immune checkpoint blockade (ICB) strategies, TB enhanced the antitumor activities of lung cancer by phototherapy and immunotherapy.
The present work developed a type of biomimetic AIEgens, which overcame the inherent limitations of conventional AIEgens and leveraged immune recognition for targeted tumor accumulation. Furthermore, the integration of AIE-driven phototherapy with immune checkpoint blockade demonstrated potent synergistic antitumor efficacy, establishing a promising combinatorial strategy against aggressive lung malignancies.
肺癌已成为目前最致命的癌症之一。传统治疗方法对肺癌的治疗效果有限。光疗法已成为一种治疗肺癌的有效方法。聚集诱导发光分子(AIEgens)具有优异的光学性能,如强荧光、聚集后增强的活性氧(ROS)生成以及有效的热效应,在光疗法中显示出巨大潜力。然而,其疏水性、低特异性和短循环寿命等缺点限制了它们在癌症治疗中的疗效。
我们开发了一种仿生AIEgens,它利用CD8 T细胞膜伪装AIEgen CHNOS(命名为BITT)纳米颗粒(称为TB)。制备的TB分别通过CD8 T细胞膜和LLC细胞膜上的PD - 1/PD - L1识别提高了AIEgen在肿瘤部位的积累。
制备的TB显示出提高的结合效率、光热效应和ROS生成能力,能够杀死肺癌细胞。TB还显示出延长的循环寿命和优异的肿瘤靶向能力,基于BITT和CD8 T细胞衍生的膜在体内实现了有效的光疗和免疫治疗。基于AIE和免疫检查点阻断(ICB)策略,TB通过光疗和免疫治疗增强了肺癌的抗肿瘤活性。
本研究开发了一种仿生AIEgens,克服了传统AIEgens的固有局限性,并利用免疫识别实现靶向肿瘤积累。此外,AIE驱动的光疗与免疫检查点阻断的整合显示出强大的协同抗肿瘤疗效,建立了一种针对侵袭性肺恶性肿瘤的有前景的联合策略。